Clinical Trial Update: Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a combination of orelabrutinib, sintilimab, and temozolomide for relapsed or refractory central nervous system lymphoma is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Hodgkin Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)
• Sintilimab (sintilimab)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Primary Central Nervous System Hodgkin Lymphoma | Phase 2 | Status: RECRUITING